ADENOSINE INJECTION SOLUTION

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

ADENOSINE

Beschikbaar vanaf:

FRESENIUS KABI CANADA LTD

ATC-code:

C01EB10

INN (Algemene Internationale Benaming):

ADENOSINE

Dosering:

3MG

farmaceutische vorm:

SOLUTION

Samenstelling:

ADENOSINE 3MG

Toedieningsweg:

INTRAVENOUS

Eenheden in pakket:

10X4ML

Prescription-type:

Prescription

Therapeutisch gebied:

CLASS IV ANTIARRYTHMICS

Product samenvatting:

Active ingredient group (AIG) number: 0113219001; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2016-09-09

Productkenmerken

PRODUCT MONOGRAPH
PR ADENOSINE INJECTION
3 mg / mL
6 mg / 2 mL Vial
6 mg / 2 mL Prefilled Syringe
12 mg / 4 mL Prefilled Syringe
Sterile Solution
USP
Antiarrhythmic
FRESENIUS KABI CANADA LTD.
Date of Revision:
45 Vogell Rd, Suite 200
September 06, 2016
Richmond Hill, ON, L4B 3P6
Control No: 187183
_Adenosine-PM-ENG-v6.0 _
_ _
_Page 2 of 18 _
PRODUCT MONOGRAPH
PR ADENOSINE INJECTION
3 MG / ML
6 MG / 2 ML VIAL
6 MG / 2 ML PREFILLED SYRINGE
12 MG / 4 ML PREFILLED SYRINGE
USP
ANTIARRHYTHMIC
ACTION AND CLINICAL PHARMACOLOGY
Adenosine is an endogenous nucleoside occurring in all cells of the
body. When injected
intravenously, adenosine slows atrioventricular (AV) nodal conduction,
can interrupt the reentry
pathways through the atrioventricular (AV) node and can restore normal
sinus rhythm in patients
with paroxysmal supraventricular tachycardia (PSVT), including PSVT
associated with Wolff-
Parkinson-White syndrome.
Adenosine is antagonized competitively by methylxanthines such as
caffeine and theophylline,
and potentiated by blockers of nucleoside transport such as
dipyridamole. Adenosine is not
blocked by atropine.
In controlled clinical trials, cumulative 60% and 92% of patients
converted to normal sinus
rhythm within one minute after 6 mg and 12 mg bolus doses of
adenosine, respectively. In other
controlled clinical trials with bolus doses of 3, 6, 9, and 12 mg,
some patients with paroxysmal
supraventricular tachycardia converted to normal sinus rhythm on 3 mg
of adenosine. Reports in
the medical literature indicate success in treating paroxysmal
supraventricular tachycardia
(PSVT) in pediatric patients (including newborns) with adenosine in
doses equivalent by weight
to those used in adults.
Adenosine is not effective in converting rhythms other than paroxysmal
supraventricular
tachycardia (PSVT), such as atrial flutter, atrial fibrillation, or
ventricular tachycardia to normal
sinus rhythm.
HEMODYNAMICS
Adenosine is a potent vasodilator in most vascular beds, except in
renal afferent arterioles and
hepatic veins w